Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Schizophrenia risk higher among relatives of affected individuals 

Key clinical point: Schizophrenia risk is higher among first-degree relatives (FDRs) of schizophrenia probands, which increases with the number of affected probands.

Major finding: Schizophrenia risk was 8-fold for FDRs of 1 proband with schizophrenia vs. healthy control probands (odds ratio [OR], 7.69; 95% CI, 5.11-11.56). The risk increased to 11-fold for relatives with 2 schizophrenic probands (OR, 11.11; 95% CI, 1.45-85.02).

Study details: Meta-analysis of 19 studies including 4,875 at-risk relatives and 5,070 control relatives.

Disclosures: This study was supported by the University of New South Wales, Sydney. Dr. Bettina Meiser had a remunerated consultant role with the company AstraZeneca with respect to an unrelated project. The other authors declared no conflict of interest.

Citation:

LE L et al. Psychiatry Res. 2020 Feb 5. doi: 10.1016/j.psychres.2020.112852.